APPENDIX A 
MEMORIAL HOSPITAL 
1275 YORK AVENUE 
NEW YORK, NEW YORK 10021 
PATIENT INFORMED CONSENT FOR CLINICAL RESEARCH 
You are being asked to participate in a clinical research study. The doctors at 
Memorial Hospital study the nature of disease and attempt to develop improved 
methods of diagnosis and treatment. This is called clinical research. In order to 
decide whether or not you should agree to be part of this research study, you 
should understand enough about its risks and benefits to make an informed 
judgment. This process is known as informed consent. 
This consent form gives detailed information about the research study which the 
doctor will discuss with you. Once you understand the study, you will be asked to 
sign this form if you wish to participate. You will have a copy to keep as a record. 
The research study being proposed to you is: 
A PILOT STUDY OF IMMUNIZATION WITH HLA-A2 MATCHED 
ALLOGENEIC RENAL CARCINOMA CELLS THAT HAVE BEEN ALTERED 
TO SECRETE INTERLEUKIN-2 IN PATIENTS WITH RENAL CELL 
CARCINOMA. 
PURPOSE OF THE RESEARCH STUDY 
Metastatic renal cell carcinoma is a disease which is resistant to standard treatment 
with chemotherapy or hormonal therapy. In rare patients, the cancer has 
spontaneously disappeared. This has suggested that an individual patient’s immune 
system can be capable of fighting the cancer. For these reasons, novel treatments 
that can increase an individual’s immune response against his/her kidney cancer are 
being studied. 
The purpose of this study is to evaluate a vaccine made as a result of the new 
technique called gene therapy. The vaccine is made from tumor cells that have been 
altered by gene therapy in order to make interleukin-2 (IL-2). Interleukin-2 is a 
protein made by certain blood cells that can stimulate an immune response. In 
Recombinant DNA Research, Volume 15 
[937] 
